Mechanism of carbapenem resistance in Klebsiella pneumoniae and antimicrobial treatment strategy
10.3969/j.issn.1673-4130.2025.15.013
- VernacularTitle:肺炎克雷伯菌对碳青霉烯耐药机制及抗菌药物治疗策略
- Author:
Hong CHEN
1
;
Mei KANG
Author Information
1. 四川大学华西医院门诊采血中心,四川 成都 610041
- Keywords:
Klebsiella pneumoniae;
carbapenem resistance;
mechanisms of resistance;
antimicrobial
- From:
International Journal of Laboratory Medicine
2025;46(15):1867-1872,1878
- CountryChina
- Language:Chinese
-
Abstract:
Klebsiella pneumoniae is a bacterium belonging to the Enterobacteriaceae.Among pathogenic Klebsiella genera,Klebsiella pneumoniae infections are the most common and are prone to hospital-acquired infections.Infections caused by carbapenem-resistant Klebsiella pneumoniae(CRKP)pose a significant risk to human health and have evolved into a global public health challenge.The resistance mechanism of CRKP is complex,mainly producing a carbapenemase enzyme.Currently,the main treatment for CRKP is the use of an-timicrobial.For the research and practice of anti-infective treatment,both domestically and abroad,the gener-ally accepted view is to use Tigecycline,Polymyxin or carbapenems as the core,and then with the use of other antimicrobial drugs,to achieve the best therapeutic effect.Another is the choice of new antimicrobial therapy,including Eravacycline,Aztreonam-Avibactam,Cefiderocol,Meropenem-Vaborbactam,Imipenem-Relebactam,and so on.This article summarizes the status of research on drug resistance mechanisms and therapeutic strat-egies of CRKP.
